

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 015280-371100US
Client Ref. No.: E-230-98/0
Customer No.: 20350

#8

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



On March 23, 2004

TOWNSEND and TOWNSEND and CREW LLP

By:


Dana Kane

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

RYBAK and NEWTON

Application No.: 09/807,556

Filed: July 30, 2001

For: SELECTIVE TOXICITY OF
AMINO-TERMINAL MODIFIED RNase
A SUPERFAMILY POLYPEPTIDES

Confirmation No. 9130

Examiner: Not yet assigned

Art Unit: 1633

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, mailed October 23, 2003, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the application as set forth below.

The **Amendments to the Specification** begin on page 3 of this paper.

Appl. No. 09/807,556

Amdt. dated March 23, 2004

Reply to Notification to Comply of October 23, 2003

PATENT

The **Amendments to the Claims** are reflected in the listing of claims which begins on page 8 of this paper.

The **Remarks** section begin on page 12 of this paper.